National Institute of Mental Health; Amended Notice of Meeting, 68083 [2020-23705]

Download as PDF Federal Register / Vol. 85, No. 208 / Tuesday, October 27, 2020 / Notices Tso, Roselyn In alphabetical order, Mr. Christopher Mandregan should be listed as a member of the Indian Health Service Performance Review Board. Membership should read as: • Mandregan, Christopher The other members listed remain as originally published. Michael D. Weahkee, Assistant Surgeon General, RADM, U.S. Public Health Service, Director, Indian Health Service. [FR Doc. 2020–23713 Filed 10–26–20; 8:45 am] BILLING CODE 4165–16–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting jbell on DSKJLSW7X2PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Conflict SEP for NIDA–L. Date: November 18, 2020. Time: 11:00 a.m. to 12:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Sheila Pirooznia, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Review, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 496–9350, sheila.pirooznia@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) VerDate Sep<11>2014 18:26 Oct 26, 2020 Jkt 253001 Dated: October 21, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–23679 Filed 10–26–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute of Mental Health Special Emphasis Panel, November 9, 2020, 12:00 p.m. to November 9, 2020, 05:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD, 20852 which was published in the Federal Register on October 16, 2020, 85 FR 65855. This notice is being amended to change the meeting date for ERB I–01 from November 9, 2020 to November 19, 2020. The time remains the same. The meeting is closed to the public. Dated: October 21, 2020. Patricia B. Hansberger, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–23705 Filed 10–26–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Avant-Garde Award and Avenir Award Programs for HIV/AIDS and Substance Use Disorder Research (DP1, DP2). Date: December 14, 2020. PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 68083 Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Yvonne Owens Ferguson, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, 3WFN 9th Floor, MSC 6021, 301 North Stonestreet Avenue, Bethesda, MD 20892, (301) 402–7371, yvonne.ferguson@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: October 21, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–23678 Filed 10–26–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed). Date: November 20–23, 2020. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F52, Rockville, MD 20892, (Virtual Meeting). Contact Person: Margaret A. Morris Fears, Ph.D., Scientific Review Officer, Scientific E:\FR\FM\27OCN1.SGM 27OCN1

Agencies

[Federal Register Volume 85, Number 208 (Tuesday, October 27, 2020)]
[Notices]
[Page 68083]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-23705]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Mental Health; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Institute of Mental Health Special Emphasis Panel, November 9, 2020, 
12:00 p.m. to November 9, 2020, 05:00 p.m., National Institutes of 
Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD, 
20852 which was published in the Federal Register on October 16, 2020, 
85 FR 65855.
    This notice is being amended to change the meeting date for ERB I-
01 from November 9, 2020 to November 19, 2020. The time remains the 
same. The meeting is closed to the public.

    Dated: October 21, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2020-23705 Filed 10-26-20; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.